Canine orosomucoid (alpha‐1 acid glycoprotein) variants and their influence on drug plasma protein binding. Issue 1 (3rd August 2020)

• Record Type: Journal Article
• Authors: Costa, Ana P.; Court, Michael H.; Villarino, Nicolas F.; Burke, Neal S.; Mealey, Katrina L.
• Is Part Of: Journal of veterinary pharmacology and therapeutics. Volume 44:Issue 1(2021)
• Page Start: 116
• Page End: 125
• Publication Date: 2020-08-03
• Subjects: dogs -- pharmacokinetics -- polymorphism -- unbound drug -- α1 acid glycoprotein; Veterinary pharmacology -- Periodicals; Therapeutics -- Periodicals; 636.0895105
• DOI: 10.1111/jvp.12899
• Languages: English
• ISSNs: 0140-7783

Abstract

Abstract: Orosomucoid polymorphisms influence plasma drug binding in humans; however, canine variants and their effect on drug plasma protein binding have not yet been reported. In this study, the orosomucoid gene (ORM1) was sequenced in 100 dogs to identify the most common variant and its allele frequency determined in 1, 464 dogs (from 64 breeds and mixed‐breed dogs). Plasma protein binding extent of amitriptyline, indinavir, verapamil, and lidocaine were evaluated by equilibrium dialysis using plasma from ORM1 genotyped dogs ( n = 12). Free and total drug plasma concentrations were quantified by liquid chromatography–mass spectrometry. From the five polymorphisms identified in canine ORM1, two were nonsynonymous. The most common was c.70G>A (p.Ala24Thr) with an allele frequency of 11.2% ( n = 1464). Variant allele frequencies varied by breed, reaching 74% in Shetland Sheepdogs ( n = 21). Free drug fractions did not differ significantly ( p > .05; Mann‐Whitney U ) between plasma collected from dogs with c.70AA ( n = 4) and those with c.70GG ( n = 8) genotypes. While c.70G>A did not affect the extent of plasma protein binding in our study, the potential biological and pharmacological implication of this newly discovered ORM1 variant in dogs should be further investigated.